Federal Judge Hints at Protection for Government in Drug Pricing Battle with Boehringer Ingelheim
In a recent judicial hearing, a judge from the Second Circuit hinted that the federal government might be protected against lawsuits challenging its push for reduced medication prices for Medicare and Medicaid beneficiaries. During the proceedings, the focus was on a case involving Boehringer Ingelheim, a prominent pharmaceutical company, which has raised concerns about the mandates affecting their pricing structures. The debate centers on whether federal mandates for lowering drug prices for government-supported health programs stand on solid legal ground or if they infringe upon the rights of pharmaceutical companies. The judge’s commentary suggested a … Read more